With Iconovo’s inhalation experience and capabilities we can develop our main pipeline candidate at a high speed. Iconovo’s flexible way of working allows us to take a stepwise development approach, enabling us to decrease the financial risk, without losing valuable time. Iconovo´s unique expertise in inhalation combined with our therapeutic focus on rare lung diseases is a great match for Kiox” says Mikkel Walmar, CEO of Kiox Pharma.

About Kiox Pharma

Kiox Pharma is a rare lung disease company located in Denmark. Kiox’ aim is to develop treatments for rare lung diseases with a high unmet need.

About the project

Kiox Pharma’s most advanced drug candidate is an inhaled treatment for interstitial lung diseases. The aim of the project is to reformulate an already FDA approved drug substance into a dry-powder based inhalation product, using one of Iconovo’s patented inhalers; ICOcap. Iconovo aims to support Kiox Pharma with pharmaceutical development from initial formulation feasibility studies, dose range determination using animal pharmacokinetic studies (together with a partner company) into a complete inhalation product.